-
Je něco špatně v tomto záznamu ?
Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation
K. Syrová, K. Šíchová, H. Danda, E. Lhotková, P. Jorratt, N. Pinterová-Leca, Č. Vejmola, L. Olejníková-Ladislavová, K. Hájková, M. Kuchař, J. Horáček, T. Páleníček
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
- Publikační typ
- časopisecké články MeSH
Introduction:N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe (2-(8-bromo-2,3,6,7-tetrahydrobenzo [1,2-b:4,5-b']difuran-4-yl)-N-[(2-methoxybenzyl]ethan-1-amine), an analogue of popular psychedelic entactogen 2C-B (4-Bromo-2,5-dimethoxyphenethylamine). Methods: All experiments were conducted on adult male Wistar rats. Pharmacokinetic parameters of 2C-B-Fly-NBOMe (1 mg/kg subcutaneously; s. c.) in blood serum and brain tissue were analysed over 24 h using liquid chromatography-mass spectrometry (LC/MS). For examination of behavioural parameters in open field test (OFT) and prepulse inhibition (PPI) of acoustic startle reaction (ASR), 2C-B-Fly-NBOMe (0.2, 1 and 5 mg/kg s. c.) was administered in two temporal onsets: 15 and 60 min after administration. Thermoregulatory changes were evaluated in individually and group-housed animals over 8 h following the highest dose used in behavioural experiments (5 mg/kg s. c.). Results: Peak drug concentrations were detected 30 and 60 min after the drug application in serum (28 ng/ml) and brain tissue (171 ng/g), respectively. The parental compound was still present in the brain 8 h after administration. Locomotor activity was dose-dependently reduced by the drug in both temporal testing onsets. ASR was also strongly disrupted in both temporal onsets, drug's effect on PPI was weaker. 2C-B-Fly-NBOMe did not cause any significant thermoregulatory changes. Discussion: Our results suggest that 2C-B-Fly-NBOMe penetrates animal brain tissue in a relatively slow manner, induces significant inhibitory effects on motor performance, and attenuates sensorimotor gating. Its overall profile is similar to closely related analogue 2C-B and other NBOMe substances.
3rd Faculty of Medicine Charles University Prague Czechia
Psychedelics Research Centre National Institute of Mental Health Prague Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23002718
- 003
- CZ-PrNML
- 005
- 20231213104545.0
- 007
- ta
- 008
- 230413s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2023.1120419 $2 doi
- 035 __
- $a (PubMed)36969854
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Syrová, Kateřina $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 245 10
- $a Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation / $c K. Syrová, K. Šíchová, H. Danda, E. Lhotková, P. Jorratt, N. Pinterová-Leca, Č. Vejmola, L. Olejníková-Ladislavová, K. Hájková, M. Kuchař, J. Horáček, T. Páleníček
- 520 9_
- $a Introduction:N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe (2-(8-bromo-2,3,6,7-tetrahydrobenzo [1,2-b:4,5-b']difuran-4-yl)-N-[(2-methoxybenzyl]ethan-1-amine), an analogue of popular psychedelic entactogen 2C-B (4-Bromo-2,5-dimethoxyphenethylamine). Methods: All experiments were conducted on adult male Wistar rats. Pharmacokinetic parameters of 2C-B-Fly-NBOMe (1 mg/kg subcutaneously; s. c.) in blood serum and brain tissue were analysed over 24 h using liquid chromatography-mass spectrometry (LC/MS). For examination of behavioural parameters in open field test (OFT) and prepulse inhibition (PPI) of acoustic startle reaction (ASR), 2C-B-Fly-NBOMe (0.2, 1 and 5 mg/kg s. c.) was administered in two temporal onsets: 15 and 60 min after administration. Thermoregulatory changes were evaluated in individually and group-housed animals over 8 h following the highest dose used in behavioural experiments (5 mg/kg s. c.). Results: Peak drug concentrations were detected 30 and 60 min after the drug application in serum (28 ng/ml) and brain tissue (171 ng/g), respectively. The parental compound was still present in the brain 8 h after administration. Locomotor activity was dose-dependently reduced by the drug in both temporal testing onsets. ASR was also strongly disrupted in both temporal onsets, drug's effect on PPI was weaker. 2C-B-Fly-NBOMe did not cause any significant thermoregulatory changes. Discussion: Our results suggest that 2C-B-Fly-NBOMe penetrates animal brain tissue in a relatively slow manner, induces significant inhibitory effects on motor performance, and attenuates sensorimotor gating. Its overall profile is similar to closely related analogue 2C-B and other NBOMe substances.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šíchová, Klára $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia
- 700 1_
- $a Danda, Hynek, $d 1988- $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia $7 xx0311507
- 700 1_
- $a Lhotková, Eva $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia
- 700 1_
- $a Jorratt, Pascal $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Pinterová-Leca, Nikola $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Vejmola, Čestmír $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Olejníková-Ladislavová, Lucie $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Hájková, Kateřina $u Forensic Laboratory of Biologically Active Compounds, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Prague, Czechia
- 700 1_
- $a Kuchař, Martin $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Forensic Laboratory of Biologically Active Compounds, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Prague, Czechia
- 700 1_
- $a Horáček, Jiří $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Páleníček, Tomáš $u Psychedelics Research Centre, National Institute of Mental Health, Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 14, č. - (2023), s. 1120419
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36969854 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230413 $b ABA008
- 991 __
- $a 20231213104541 $b ABA008
- 999 __
- $a ok $b bmc $g 1922641 $s 1188925
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 14 $c - $d 1120419 $e 20230309 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20230413